Skip to main content

Table 2 Demographic and clinical characteristics of the patients at enrolment*

From: Artemisinin-naphthoquine plus lower-dose primaquine to treat and prevent recurrence of Plasmodium vivax malaria: an open-label randomized and non-inferiority trial

Characteristics

ANPQ3 group (N = 177)

CQPQ14 group (N = 130)

Demographic

 Median age (range)—years

19 (5–59)

19 (5–67)

 Male—no. (%)

97 (54.8)

76 (58.5)

Clinical

 Median weight (range)—kg

50.0 (10.0–76.0)

50.0 (12.0–70.0)

 Temperature ± SD (range)—oC

38.2 ± 1.0 (35.4–40.5)

38.2 ± 1.0 (35.6–42.0)

 Geometric mean parasite count (range)—/ul

3348 (174–65,418)

4144 (100–105,666)

  1. SD standard deviation
  2. *ANPQ3 denotes artemisinin-naphthoquine plus primaquine for 3 days; CQPQ14 denotes chloroquine plus primaquine for 14 days